Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc.

"Acquisition Includes QLS-215, a Potential Best-in-Class Monoclonal Antibody Inhibitor of Plasma Kallikrein in Preclinical Development fo


r the Treatment of Hereditary Angioedema



Company Plans to Use Private Placement Financing Proceeds of $110 Million to Complete IND-Enabling Studies, Pha

se 1a and Phase 1b/2 Clinical Trials of QLS-215..."


020121 Catabasis Pharmaceuticals Announc
.
Download • 243KB